Cellectar Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CLRB research report →
Range $11 – $11
Price Chart
About the company
Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies.
- CEO
- James V. Caruso
- IPO
- 2005
- Employees
- 11
- HQ
- Florham Park, NJ, US
Get TickerSpark's AI analysis on CLRB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $8.00M
- P/E
- -0.23
- Fwd P/E
- 8.41
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.65
- EV/EBITDA
- 0.57
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -154.53%
- ROIC
- -111.85%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-213,597+0.0%
- Op Income
- $-22,979,844
- Net Income
- $-21,791,037+51.1%
- EPS
- $-8.35+77.1%
- OCF Growth
- +51.4%
- FCF Growth
- +51.5%
- 52W High
- $4.70
- 52W Low
- $0.76
- 50D MA
- $1.48
- 200D MA
- $2.46
- Beta
- 0.58
- RSI (14)
- 22
- Avg Volume
- 97.96K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Cellectar said it is on track to start its confirmatory phase III trial in Q1 2027 and believes Iopofosine could be commercially available as early as late 2027 or early 2028.· November 10, 2026
- Cash and cash equivalents were approximately $24.6 million at quarter-end, and management said runway extends into Q2 2027.
- Q3 net loss was $8.0 million, or $0.46 per share, versus $4.4 million, or $1.41 per share, a year ago.
- R&D expense rose to about $5.4 million from $2.5 million, mainly due to phase III startup and higher CLR 125 activity; G&A increased to $2.7 million from $2.3 million.
- Management said the confirmatory phase III trial remains on track for first patient dosing in Q1 2027 and NDA submission is targeted for 1H 2027.
- The company highlighted WM data showing a 79.2% major response rate and 16-month median duration of response in a BTKi-pretreated subgroup, plus a 2025 ASH presentation slate.
Cellectar reported third-quarter 2026 cash and cash equivalents of approximately $24.6 million, up from $13.2 million at December 31, 2025. R&D expense was approximately $5.4 million versus $2.5 million in Q3 2025, G&A was $2.7 million versus $2.3 million, and net loss was $8.0 million, or $0.46 per share, versus $4.4 million, or $1.41 per share, a year ago. Management said the cash runway extends into Q2 2027. Forward-looking targets include first patient dosing in the confirmatory phase III study in Q1 2027, NDA submission in the first half of 2027, and potential U.S. commercial availability as early as late 2027 or early 2028.
Jim Caruso framed the quarter as strategically important, saying the company is entering its most significant value-creating phase as it advances toward accelerated approval and potential commercialization of Iopofosine I-131 in relapsed/refractory WM. He emphasized continued de-risking across clinical, regulatory, and operational work, including phase III startup, phase I-B dosimetry, and the planned NDA filing. His tone was optimistic and execution-focused, repeatedly describing the opportunity as transformational and highlighting support from the balance sheet.
Chad Kolean focused on liquidity and expense trends. He said the company ended Q3 with approximately $24.6 million in cash and cash equivalents, following the earlier oversubscribed financing of up to $140 million, and said runway extends into Q2 2027. He also cited R&D of about $5.4 million, up from $2.5 million, driven by phase III initiation and CLR 125 work, G&A of $2.7 million versus $2.3 million, and a net loss of $8.0 million, or $0.46 per share.
The most detailed questions centered on whether the phase I-B dosimetry study would compete with phase III enrollment and how many patients must be enrolled before filing. Management said the studies should not materially conflict because they will use largely different sites, different patient access points, and dosimetry-focused centers, and said the phase I-B may even provide visibility into earlier-line activity. On filing readiness, management said the FDA has been intentionally vague, but they believe 5% to 15% enrollment by regulatory action could be a practical target, and that the confirmatory program is designed to meet the accelerated approval framework.
Management believes the lead WM program is gaining momentum clinically and operationally, with a clear accelerated approval path, phase III startup underway, and NDA timing set for 1H 2027. They also pointed to encouraging efficacy data in a difficult BTKi-pretreated subgroup, plus the possibility that earlier-line use could improve response durability and safety, broadening the commercial opportunity.
The company still has only approximately $24.6 million in cash and expects runway only into Q2 2027, so execution must stay on schedule to reach key milestones. Management also acknowledged uncertainty around FDA expectations for how much phase III enrollment is needed at the time of regulatory action, and it is delaying the European submission by about 9 months because of U.S. pricing concerns tied to most-favored-nation pricing.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 98.2%
- Shares Outstanding
- 10.04M
- Float Shares
- 9.86M
of shares held by institutions
29 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Stonepine Capital Management, LLC | 749.03K | ▲ 644.48K |
| Caligan Partners LP | 470.00K | ▲ 470.00K |
| Stempoint Capital LP | 354.94K | ▲ 354.94K |
| Vanguard Capital Management LLC | 310.90K | ▼ 16.47K |
| Bleichroeder LP | 288.68K | 0 |
| Jupiter Topco LLC | 274.16K | ▲ 274.16K |
| Balyasny Asset Management L.P. | 220.00K | ▲ 220.00K |
| Nantahala Capital Management, LLC | 220.00K | 0 |
| Empery Asset Management, LP | 189.60K | ▲ 189.60K |
| Silverarc Capital Management, LLC | 151.12K | ▼ 170.61K |
| Diadema Partners LP | 138.34K | ▲ 138.34K |
| Vanguard Group Inc | 89.12K | ▲ 23.95K |
Held by 19 ETFs
Biggest fund positions in CLRB by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 8, 26 | Loren Stefan | other | 15,000 |
| Jul 7, 26 | Kolean Chad J | other | 92,000 |
| Jul 7, 26 | DRISCOLL FREDERICK W | other | 25,000 |
| Jul 7, 26 | Chanan-Khan Asher | other | 25,000 |
| Jul 7, 26 | CARUSO JAMES V | other | 250,000 |
| Jul 7, 26 | Gu Andrew | other | 25,000 |
| Jul 7, 26 | Longcor Jarrod | other | 118,000 |
| Jul 7, 26 | Swirsky Douglas J | other | 37,500 |
| Jul 7, 26 | NEIS JOHN | other | 25,000 |
| Jul 8, 26 | Loren Stefan | other | 15,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CLRB coverage
Recent articles, reports, and earnings notes.
No research on CLRB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CLRB report →Cellectar Biosciences, Inc. (CLRB) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 11
Cellectar Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
globenewswire.com · Nov 10
Cellectar Biosciences to Present Three Posters Highlighting Durable Clinical Activity of Iopofosine I 131 in Waldenström Macroglobulinemia at the American Society of Hematology Annual Meeting and Exposition
globenewswire.com · Nov 4
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Tuesday, November 10, 2026
globenewswire.com · Nov 2
Cellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131
globenewswire.com · Oct 27
Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström Macroglobulinemia
globenewswire.com · Oct 15
Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström Macroglobulinemia
globenewswire.com · Sep 29
Cellectar Biosciences, Inc. (CLRB) Discusses Scientific Rationale and Potential of Phospholipid Ether Platform in Targeted Cancer Therapy Transcript
seekingalpha.com · Aug 18
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.